Posts by Andrew Mahoney

Last week, Bobby Moy, managing director of Clarion, a Lumanity business, attended the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California. Here, he shares four key takeaways from the conference: Are you a company that is looking for guidance in the rare disorder and/or gene therapy…

By: Dennis Chang Oncology drug development has produced remarkable breakthroughs in the last decade, including various immunotherapies and precision medicine approaches, offering hope for previously incurable cancers. However, the probability of success (PoS) in oncology is among the lowest of all therapeutic areas: the likelihood of regulatory approval for programs entering Phase 1 is only…